Human VEGF165, recombinant

VEGF (or VEGF-A) is a disulfide-linked dimeric growth factor, a member of the PDGF family, with an amino acid sequence containing eight cysteine residues that form a conserved disulfide linkage. VEGF is required during embryogenesis to regulate endothelial cell proliferation, migration and survival. In adults, VEGF acts mainly in wound healing and in the female reproductive cycle. Pathologically, it is involved in tumour angiogenesis and vascular leakage. VEGF is produced by cells such as endothelial cells, macrophages and T cells. At least five isoforms with different amino acid lengths, such as VEGF121, VEGF145, VEGF165, VEGF185, and VEGF206, are present in the human body due to different shearing of mRNA. Among them, VEGF165 is the most abundant and potent isoform with potent pro-angiogenic effects, stimulating endothelial cell proliferation and survival, promoting angiogenesis and increasing vascular permeability. Recombinant human VEGF165 protein is expressed by E.coli, and is produced with raw materials of pharmaceutical applicable level. The host protein residue, nucleic acid residue and common pathogens are strictly controlled, and the production and quality management procedures of the product comply with GMP regulations to ensure the traceability of the production process and all raw materials.